Study guide
5.2 Systemic Medications and Drug Interactions in Dentistry
Integrated National Board Dental Examination INBDE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: INBDE Exam Structure & Test Specifications
1.1 INBDE Format, Administration, Scoring & Retesting 1.2 The Domain of Dentistry: Test Specifications, Item Formats, Patient Boxes & Dental Charts
2 Chapter 2: Foundation Knowledge — Anatomic Sciences & Development
2.1 Gross & Head/Neck Anatomy and Histology 2.2 Oral Embryology, Tooth Development & Eruption 2.3 Genetic, Congenital & Developmental Conditions
3 Chapter 3: Foundation Knowledge — Biochemistry, Physiology & Physical Sciences
3.1 Biochemistry and Systemic Physiology 3.2 Physics & Chemistry of Oral Biology: pH, Diffusion & Demineralization
4 Chapter 4: Foundation Knowledge — Pathology, Microbiology & Immunology
4.1 General & Systemic Pathology 4.2 Microbiology, Immunology, and Infection Pathogenesis
5 Chapter 5: Foundation Knowledge — Pharmacology
5.1 Dental Pharmacology, Local Anesthetics, and Analgesics 5.2 Systemic Medications and Drug Interactions in Dentistry
6 Chapter 6: Foundation Knowledge — Dental Anatomy, Occlusion & Materials
6.1 Tooth Morphology, Anatomy, and Occlusion Biomechanics 6.2 Dental Materials Science, Biomaterials, and Impression Systems
7 Chapter 7: Patient Evaluation & Data Gathering
7.1 Chief Complaint, History Taking & Information from Diverse Sources 7.2 Comprehensive Patient History, Examination, and Medical Risk Assessment 7.3 Vital Signs, ASA Physical Status & Medical Risk Stratification 7.4 Normal Findings vs Significant Deviations Requiring Management
8 Chapter 8: Diagnostic Imaging
8.1 Dental Radiology Physics, Safety, and Imaging Interpretation 8.2 Intraoral Radiographic Technique, Errors & Quality Assurance 8.3 Radiographic Interpretation of Caries, Periapical & Bone Lesions 8.4 Panoramic, CBCT & Selection Criteria for Advanced Imaging
9 Chapter 9: Diagnostic Reasoning & Systemic Assessment
9.1 Diagnostic Testing, Laboratory Values, and Medical Complexities 9.2 Predictive Diagnostic Reasoning & Selecting the Right Diagnostic Test 9.3 Oral–Systemic Interrelationships 9.4 Differential Diagnosis of Orofacial Pain
10 Chapter 10: Oral Pathology & Mucosal Disease
10.1 Benign and Malignant Oral Pathology and Biopsy Protocols 10.2 Managing Oral Mucosal and Osseous Diseases
11 Chapter 11: Treatment Planning, Prognosis & Communication
11.1 Interdisciplinary Treatment Planning Sequencing and Prognosis 11.2 Prognosis Determination & Presenting Treatment Alternatives 11.3 Informed Consent, Refusal & Patient Education 11.4 Patient Attributes, Culture, Social Background & Care Across the Lifespan 11.5 Psychological, Social & Behavioral Principles in Patient Communication 11.6 Evaluating the Outcomes of Comprehensive Dental Care
12 Chapter 12: Medical & Dental Emergencies
12.1 Dental and Medical Emergencies in the Dental Office 12.2 Recognizing and Triaging Dental Emergencies
13 Chapter 13: Caries, Operative & Esthetic Dentistry
13.1 Caries Risk Assessment, Prevention, and Operative Dentistry 13.2 Adhesive Dentistry, Composite/Amalgam Restorations, and Esthetics 13.3 Managing the Esthetic Needs of Patients
14 Chapter 14: Endodontics
14.1 Pulpal Biology, Endodontic Diagnosis, and Emergency Treatment 14.2 Endodontic Therapy, Root Canal Instrumentation, Obturation, and Surgery
15 Chapter 15: Periodontics & Implantology
15.1 Periodontal Pathogenesis, Etiology, and Disease Classification 15.2 Non-Surgical Periodontal Therapy and Maintenance Protocols 15.3 Surgical Periodontics, Mucogingival Procedures, and Regenerative Care 15.4 Dental Implants: Planning, Surgical Placement, and Restorative Options
16 Chapter 16: Prosthodontics & Laboratory Communication
16.1 Fixed Prosthodontics: Crown/Bridge Preparation, Design, and Cementation 16.2 Removable Complete Dentures: Impression, Occlusion, and Delivery 16.3 Removable Partial Dentures: Components, Design, and Frameworks 16.4 Communicating Case Design to the Dental Laboratory
17 Chapter 17: Pain Control, Anesthesia & Oral Surgery
17.1 Local Anesthetic Techniques, Complications, and Nitrous Oxide Sedation 17.2 Dentoalveolar Surgery, Tooth Extraction, and Surgical Complications 17.3 Maxillofacial Trauma, Odontogenic Infections, and Complex Surgery
18 Chapter 18: Occlusion, TMD & Orthodontics
18.1 Craniofacial Growth, Development, and Orthodontic Diagnosis/Intervention 18.2 Developmental & Acquired Occlusal Problems 18.3 Temporomandibular Disorders: Diagnosis and Management
19 Chapter 19: Pediatric, Special Care & Vulnerable Patients
19.1 Pediatric Dental Care, Behavior Guidance, and Preventive Services 19.2 Pediatric Restorative Dentistry, Pulpal Therapy, and Dental Trauma 19.3 Special Care Dentistry: Geriatric, Special Needs, and Medically Compromised Patients 19.4 Recognizing, Managing & Reporting Patient Abuse and Neglect 19.5 Recognizing and Managing Substance Use Disorders
20 Chapter 20: Practice Management, Safety Systems & Informatics
20.1 Infection Control Protocols, Sterilization, and OSHA Compliance 20.2 Radiation Safety Guidelines, Dosimetry, and ALARA Principles 20.3 Practice Business Operations, OSHA & Regulatory Compliance 20.4 Catastrophe Preparedness & Practice Continuity Planning 20.5 Managing, Coordinating & Supervising Allied Dental Personnel 20.6 Quality Assurance, Assessment and Improvement 20.7 Dental Informatics, Electronic Records & Emerging Technology 20.8 Scope of Competence, Referral & Professional Self-Assessment
21 Chapter 21: Ethics, Jurisprudence, Evidence & Public Health
21.1 ADA Ethics Code, Jurisprudence, HIPAA, and Professional Conduct 21.2 Evidence-Based Dentistry, Clinical Epidemiology, and Dental Public Health 21.3 Biostatistics, Study Design & Critical Appraisal 21.4 Community Collaboration & Systems of Oral Health Care Delivery 21.5 Emerging Trends and Social/Economic Forces in Oral Health Care 21.6 Prevention, Intervention & Patient Education Strategies
5.2 Systemic Medications and Drug Interactions in Dentistry
Key Takeaways Explain This Topic AI
The 2021 AHA antibiotic prophylaxis guidelines restrict coverage exclusively to high-risk cardiac conditions using Amoxicillin 2g PO (or Azithromycin 500mg, Clarithromycin 500mg, or Doxycycline 100mg for penicillin allergy), with Clindamycin officially removed.
Minor oral surgery can safely proceed without stopping Warfarin therapy if the patient's International Normalized Ratio (INR) is stable and below 3.5, using local hemostatic measures.
MRONJ diagnosis requires exposed bone or a fistula in the maxillofacial region persisting >8 weeks in patients taking antiresorptive or antiangiogenic drugs with no history of radiation therapy.
Patients with severe hypertension (blood pressure >= 180/110 mmHg) must have elective dental care deferred immediately and be referred for urgent medical evaluation.
Conscious hypoglycemic episodes in diabetic patients are managed with the 'Rule of 15' (15-20g fast-acting oral carbohydrates, recheck in 15 minutes), while unconscious hypoglycemia requires EMS activation and 1 mg glucagon IM/SC.
Last updated: August 2026
2.2 Systemic Medications and Drug Interactions in Dentistry
INBDE Core Concept: Managing dental patients taking systemic medications requires precise knowledge of prophylactic antibiotic guidelines, bleeding control for antithrombotic therapy, antiresorptive-induced osteonecrosis risks, blood pressure action cutoffs, glycemic management, and immunosuppression management.
Antibiotic Prophylaxis Guidelines (2021 AHA Revisions)
The American Heart Association (AHA) and American Dental Association (ADA) restrict infective endocarditis (IE) antibiotic prophylaxis exclusively to patient groups at the highest risk of adverse outcomes from endocarditis.
Cardiac Indications for Prophylaxis
Prophylaxis is recommended ONLY for invasive dental procedures involving manipulation of gingival tissue, the periapical region of teeth, or perforation of the oral mucosa in patients with:
Prosthetic cardiac valves or prosthetic material used for cardiac valve repair (including transcatheter valves).
Previous history of Infective Endocarditis (IE) .
Uncorrected cyanotic congenital heart disease (CHD) , including palliative shunts and conduits.
Completely repaired CHD with prosthetic material or device during the first 6 months after the procedure.
Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or device.
Cardiac transplant recipients who develop cardiac valvulopathy.
INBDE Trap: Antibiotic prophylaxis is NOT recommended for mitral valve prolapse, rheumatic heart disease, bicuspid aortic valve, coronary artery stents, or prosthetic joint replacements (per ADA guidelines, routine prophylaxis for joint replacements is not supported by evidence).
Prophylactic Regimens (Administered 30–60 Minutes Prior to Procedure)
- Patient Category First-Line Antibiotic Dose (Adults) Dose (Pediatric)
- Standard Oral Regimen Amoxicillin 2.0 grams PO 50 mg/kg PO
- Unable to Take Oral Meds Ampicillin OR Cefazolin/Ceftriaxone 2.0 g IV/IM 50 mg/kg IV/IM
Penicillin Allergy (Oral) Azithromycin OR Clarithromycin OR Doxycycline 500 mg PO; 500 mg PO; 100 mg PO 15 mg/kg PO; 15 mg/kg PO; 2.2 mg/kg PO
Penicillin Allergy (NPO) Cefazolin OR Ceftriaxone 1.0 g IV/IM 50 mg/kg IV/IM
CRITICAL GUIDELINE UPDATE: Clindamycin is NO LONGER recommended by the AHA for infective endocarditis prophylaxis due to its disproportionate risk of causing severe, potentially fatal Clostridioides difficile colitis.
Anticoagulants and Antiplatelet Therapy
Dental surgical management requires balancing the risk of intraoperative hemorrhage against the risk of thromboembolic stroke or vascular occlusion. Hemostasis Spectrum:
- Thromboembolic Risk (Stopping Drug) ◄───────────────► Hemorrhage Risk (Continuing Drug)
- Target Range for Minor Surgery: Stable INR < 3.5
- Warfarin (Coumadin)
Mechanism: Vitamin K antagonist that inhibits hepatic synthesis of Vitamin K-dependent clotting factors ( II, VII, IX, X ).
Monitoring: Evaluated using the Prothrombin Time (PT) and International Normalized Ratio (INR) .
Surgical Rule: For minor oral surgical procedures (simple extractions, single implants, periodontal scaling), Warfarin should NOT be discontinued if the patient's INR is stable and < 3.5 . Local hemostatic agents (tranexamic acid mouthwash, oxidized cellulose, gelfoam, surgical sutures) effectively control local bleeding.
Direct Oral Anticoagulants (DOACs)
DOACs act directly on specific steps of the coagulation cascade and have largely replaced warfarin in clinical medicine.
Drug Class Generic Names Target Mechanism Routine Coagulation Monitoring Required?
Direct Thrombin Inhibitor Dabigatran (Pradaxa) Inhibits Factor IIa (Thrombin) No
Factor Xa Inhibitors Rivaroxaban (Xarelto), Apixaban (Eliquis), Edoxaban Direct inhibition of active Factor Xa No
Surgical Management: DOACs do not alter INR. For minor oral procedures, morning doses may be held or delayed until after surgery, but routine cessation is rarely indicated without consulting the prescribing physician.
Antiplatelet Medications
Aspirin: Irreversibly inhibits COX-1, blocking thromboxane A 2 A_2 A 2 ( T X A 2 TXA_2 TX A 2 ) synthesis for the 7–10 day lifespan of the platelet.
Clopidogrel (Plavix): Irreversibly blocks the P 2 Y 12 P2Y_{12} P 2 Y 12 adenosine diphosphate (ADP) receptor on platelets.
Surgical Management: Neither aspirin nor clopidogrel should be stopped prior to dental extractions. Discontinuation drastically increases the risk of arterial thrombosis.
Antiresorptives, Bisphosphonates, and MRONJ
Medication-Related Osteonecrosis of the Jaw (MRONJ) is a severe adverse effect associated with antiresorptive and antiangiogenic therapies that inhibit bone remodeling and angiogenesis.
Antiresorptive Drug Classes & Mechanisms
Bisphosphonates (IV: Zoledronic acid, Pamidronate; Oral: Alendronate, Risedronate, Ibandronate): Incorporate into hydroxyapatite crystals, taken up by osteoclasts during bone resorption, and inhibit farnesyl pyrophosphate synthase (FPPS) , inducing osteoclast apoptosis.
RANKL Inhibitors (Denosumab / Prolia / Xgeva): Monoclonal antibody that binds to receptor activator of nuclear factor- κ \kappa κ B ligand (RANKL), preventing osteoclast maturation and activation. Unlike bisphosphonates, denosumab does not bind bone matrix; its antiresorptive effect wanes ~6 months after cessation.
Antiangiogenic Agents (Bevacizumab, Sunitinib): Inhibit vascular endothelial growth factor (VEGF) signaling, impairing new vessel formation and bone vascularity.
Diagnostic Criteria for MRONJ (AAOMS Guidelines)
A clinical diagnosis of MRONJ requires ALL three of the following criteria:
Current or previous treatment with antiresorptive or antiangiogenic agents.
Exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region that has persisted for more than 8 weeks .
No history of radiation therapy to the jaws or obvious metastatic disease to the jaws.
MRONJ Clinical Staging & Management Strategies
MRONJ Stage Clinical Presentation Recommended Dental Management
At-Risk No exposed bone; patient taking oral or IV antiresorptive therapy Patient education, oral hygiene optimization, routine dental care
Stage 0 No bone exposure; non-specific symptoms (jaw pain, sinus pain, toothache, osteosclerosis) Symptomatic management, conservative monitoring
Stage 1 Exposed bone or fistula; asymptomatic , no evidence of infection Antimicrobial rinses (0.12% chlorhexidine), clinical re-evaluation
Stage 2 Exposed bone or fistula with pain and clinical infection (erythema, purulence) Antimicrobial rinses, systemic oral antibiotics, pain control, soft tissue debridement
Stage 3 Exposed bone extending beyond alveolar bone (pathologic fracture, extraoral fistula, inferior border defect) Surgical debridement or resection, systemic antibiotics, pain management
Dental Clinical Rules: Complete all invasive dental extractions and periodontal therapy BEFORE initiating IV bisphosphonate therapy for oncology. For patients already on oral bisphosphonates (>4 years or with risk factors), consider a 2-month drug holiday prior to elective oral surgery if cleared by the prescribing physician.
Antihypertensive Medications & Dental Management Cutoffs
High blood pressure is extremely prevalent in dental populations. Antihypertensive medications interact with vasoconstrictors and dental analgesics.
Major Antihypertensive Classes & Dental Implications
ACE Inhibitors (Lisinopril, Enalapril): Block conversion of Angiotensin I to Angiotensin II. Side effects include a persistent dry cough (due to bradykinin accumulation) and potential angioedema.
Angiotensin Receptor Blockers (ARBs - Losartan, Valsartan): Block A T 1 AT_1 A T 1 receptors directly without causing bradykinin accumulation (no dry cough).
Beta-Blockers:
Cardioselective ( β 1 \beta_1 β 1 ): Metoprolol, Atenolol. Safe with standard dental local anesthetic vasoconstrictors.
Non-Selective ( β 1 + β 2 \beta_1 + \beta_2 β 1 + β 2 ): Propranolol, Nadolol . CRITICAL DRUG INTERACTION: Exogenous epinephrine acts on unblocked vascular α 1 \alpha_1 α 1 receptors while β 2 \beta_2 β 2 vasodilation is blocked by propranolol, causing severe hypertensive crisis followed by vagal reflex bradycardia . Limit epinephrine to 0.04 mg (maximum 2 cartridges of 1:100,000 epi).
Calcium Channel Blockers (CCBs - Nifedipine, Amlodipine, Diltiazem): Inhibit L-type calcium channels in vascular smooth muscle and myocardium. Nifedipine frequently causes gingival overgrowth / hyperplasia starting in the interdental papillae.
Diuretics (Hydrochlorothiazide, Furosemide): Can cause orthostatic (postural) hypotension; advise patients to transition slowly from supine to upright dental chair positions. NSAIDs taken for >5 days attenuate the antihypertensive efficacy of diuretics and ACE inhibitors by inhibiting renal prostaglandins.
ASA Physical Status & Blood Pressure Cutoffs (2017 ACC/AHA Guidelines)
- BP Category Systolic (mmHg) Diastolic (mmHg) ASA Class Dental Management Guidelines
- Normal < 120 and < 80 ASA I Standard dental care
- Elevated 120–129 and < 80 ASA I Standard dental care; recheck next visit
- Stage 1 HTN 130–139 or 80–89 ASA II Standard dental care; discuss lifestyle changes
- Stage 2 HTN 140–179 or 90–109 ASA II / III Elective dental care permitted; implement stress reduction protocol
Hypertensive Crisis ≥ \ge ≥ 180 or ≥ \ge ≥ 110 ASA IV DEFER ALL ELECTIVE DENTAL CARE IMMEDIATELY . Refer for urgent medical evaluation. Emergency care (pain/infection) only with strict BP monitoring.
Antidiabetic Medications & Glycemic Protocols
Uncontrolled diabetes impairs neutrophil function, wound healing, and collagen synthesis, significantly exacerbating periodontal disease and surgical complication rates.
Diagnostic Thresholds & Glycemic Control
HbA1c Target: Normal < 5.7%; Well-controlled diabetic < 7.0% ; Uncontrolled diabetic > 8.0% (increased surgical infection risk).
Fasting Plasma Glucose (FPG): Target 80–130 mg/dL. Values > 200 mg/dL warrant deferral of elective surgical procedures.
Antidiabetic Pharmacotherapy
Insulin (Rapid-, Short-, Intermediate-, Long-acting): Replaces endogenous insulin in Type 1 DM and advanced Type 2 DM. Highest risk for acute hypoglycemia .
Biguanides (Metformin): First-line oral agent for Type 2 DM. Decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity. Does NOT cause hypoglycemia when used as monotherapy.
Sulfonylureas (Glipizide, Glyburide, Glimepiride): Stimulate pancreatic β \beta β -cells to secrete insulin. High risk of hypoglycemia if meal intake is skipped.
Incretin Therapies (GLP-1 Receptor Agonists - Semaglutide; DPP-4 Inhibitors - Sitagliptin): Enhance glucose-dependent insulin secretion.
Dental Management & Acute Hypoglycemia Protocol
Appointment Scheduling: Treat diabetic patients in the morning after they have taken their normal antidiabetic dose and eaten a normal breakfast (endogenous cortisol levels are highest in the morning, mitigating hypoglycemia risk).
Conscious Hypoglycemic Patient ("Rule of 15"):
Symptoms: Tremors, diaphoresis, tachycardia, confusion, dizziness.
Action: Administer 15–20 grams of fast-acting oral carbohydrates (e.g., 4 oz orange juice, 3–4 glucose tablets). Wait 15 minutes and recheck blood glucose. Repeat if blood glucose remains < 70 mg/dL.
Unconscious Hypoglycemic Patient:
Action: Call EMS (911) immediately. Maintain airway. Administer 1 mg Glucagon IM/SC or 50 mL of 50% Dextrose (D50W) IV .
Immunosuppressive Therapies, Adrenal Insufficiency, and Cytopenias
Patients undergoing organ transplantation, autoimmune disease management (e.g., rheumatoid arthritis, lupus), or cancer chemotherapy take systemic immunosuppressants.
Key Immunosuppressive Agents
Corticosteroids (Prednisone, Dexamethasone): Potent anti-inflammatory agents that suppress phospholipase A 2 A_2 A 2 and leukocyte migration. Chronic use causes secondary adrenal insufficiency.
Calcineurin Inhibitors (Cyclosporine, Tacrolimus): Block T-cell activation by inhibiting calcineurin-mediated IL-2 transcription. Cyclosporine causes gingival overgrowth / hyperplasia in ~30% of patients (combining cyclosporine with nifedipine markedly exacerbates gingival enlargement).
Biologic Response Modifiers (TNF- α \alpha α Inhibitors - Infliximab, Adalimumab): Increase susceptibility to opportunistic fungal and mycobacterial infections.
Exogenous Steroids & Adrenal Crisis ("Rule of 2s")
Exogenous steroid administration suppresses the hypothalamic-pituitary-adrenal (HPA) axis. Adrenal Suppression Risk Factors: ≥ 20 mg prednisone/day for ≥ 2 consecutive weeks within the past 2 years \text{Adrenal Suppression Risk Factors:} \quad \ge 20\text{ mg prednisone/day} \quad \text{for } \ge 2\text{ consecutive weeks} \quad \text{within the past } 2\text{ years} Adrenal Suppression Risk Factors: ≥ 20 mg prednisone/day for ≥ 2 consecutive weeks within the past 2 years
Adrenal Crisis Manifestations: Severe hypotension, hypovolemic shock, confusion, vomiting, abdominal pain.
Current Supplementation Guidelines: Routine non-surgical dental procedures and minor extractions under local anesthesia DO NOT require routine steroid stress coverage . Patients should take their normal daily morning dose. For major surgical stress (extensive multi-hour maxillofacial trauma or reconstructive surgery), consult the physician to consider doubling the daily dose on the day of surgery.
Hematologic Cytopenias & Absolute Neutrophil Count (ANC)
Blood Component Normal Range Surgical Threshold Dental Clinical Management Rules
Absolute Neutrophil Count (ANC) 1,500–8,000 / μ \mu μ L < 1,000 / μ \mu μ L ANC < 1,000 / μ \mu μ L: Requires prophylactic antibiotics prior to invasive procedures.; ANC < 500 / μ \mu μ L (Severe Neutropenia): DEFER all elective dental treatment due to extreme infection risk.
Platelet Count 150,000–450,000 / μ \mu μ L < 50,000 / μ \mu μ L Platelets < 50,000 / μ \mu μ L: Invasive dental surgery contraindicated without pre-operative platelet transfusion.; Platelets < 20,000 / μ \mu μ L: Risk of spontaneous gingival bleeding.